Stock Details
AZN is AstraZeneca PLC's stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 62.81$. Average daily volumn in 3 months 6.48M. Market cap 180.80B



Stock symbol : AZN. Exchange : NasdaqGS. Currency : USD
Lastest price : 54.84$. Total volume : 7.05M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

AstraZeneca PLC (AZN)
Last Price
54.84$
Change
-0.07
Volume
7.05M

Previous Close54.91
Open55.21
Day Range54.76-55.72
Bid54.95 x 3.1k
Ask55.00 x 3.1k
Volume7.05M
Average Volume6.48M
Market Cap180.8B
BetaN/A
52 Week Range52.65-71.70
Trailing P/EN/A
Foward P/E15.07
Dividend (Yield %)N/A
Ex-Dividend DateN/A



Financial Details


According to AstraZeneca PLC's financial reports the company's revenue in 2021 were 37.42B an increase( +42.31%) over the years 2020 revenue that were of 26.62B. In 2021 the company's total earnings were 112M while total earnings in 2020 were 3.2B(-96.27%).


Loading ...



Organization

Market Cap:
180.80B
Revenue:
37.42B
Total Assets:
105.36B
Total Cash:
6.33B


News about "AstraZeneca PLC"

astrazeneca-plc-nasdaqazn-shares-sold-by-western-wealth-management-llc-image

AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Western Wealth Management LLC

Source from : Defense World - 2 days ago

Western Wealth Management LLC reduced its position in shares of AstraZeneca PLC (NASDAQ:AZN โ€“ Get Rating) by 4.9% in the second quarter, according to the company in its most recent 13F filing with the ...See details»


AstraZeneca PLC (NASDAQ:AZN) Sees Large Decline in Short Interest

Source from : Defense World - 2 days ago

AstraZeneca PLC (NASDAQ:AZN โ€“ Get Rating) saw a significant decrease in short interest in September. As of September 15th, there was short interest totalling 6,420,000 shares, a decrease of 29.4% from ...See details»


astrazeneca-gets-its-third-regulatory-green-light-in-a-matter-of-weeks-for-asthma-drug-image

AstraZeneca gets its third regulatory green light in a matter of weeks for asthma drug

Source from : Proactive Investors - 4 days ago

The treatment has been approved in Japan for severe bronchial asthma where high-dose traditional corticosteroids donโ€™t work ...See details»


japan-approves-astrazenecas-two-treatments-for-asthma-rare-form-of-cancer-image

Japan Approves AstraZeneca's Two Treatments For Asthma, Rare Form Of Cancer

Source from : YAHOO!Finance - 3 days ago

Koselugo (selumetinib) for pediatric patients with plexiform neurofibromas (PNs) in neurofibromatosis type 1 (NF1) with clinical symptoms and which cannot be entirely removed by surgery without the ...See details»


AstraZeneca PLC (AZN): Donโ€™t disregard this ominous signal

Source from : investchronicle - 10 days ago

For the readers interested in the stock health of AstraZeneca PLC (AZN). It is currently valued at $57.40. When the transactions were called off in the previous session, Stock hit the highs of $58.025 ...See details»


AstraZeneca PLC AZNCF Stock Quote

Source from : Morningstar%2c Inc. - 5 days ago

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do ...See details»


AstraZeneca's Evusheld Drug Approved by EU for Covid-19 Treatment

Source from : MarketWatch - 11 days ago

By Joe Hoppe AstraZeneca PLC said Tuesday that its Evusheld long-acting antibody combination has been approved in the European Union for the treatment ...See details»


AstraZeneca Announces Approval For Ultomiris By The European Commission

Source from : Nasdaq - 8 days ago

(RTTNews) - AstraZeneca PLC (AZN.L, AZN) announced Ultomiris has been approved in Europe as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis who ...See details»


ADRs End Lower; AstraZeneca, Barclays Trade Actively

Source from : Morningstar%2c Inc. - 9 days ago

AstraZeneca PLC was among those companies whose ADRs traded actively. The pharmaceutical giant ticked down 1.7% following news that its tezepelumab treatment Tezspire has been approved in the ...See details»


AstraZeneca: Tezspire Gets EU Approval To Treat Severe Asthma

Source from : Nasdaq - 10 days ago

(RTTNews) - British drug major AstraZeneca Plc (AZN.L, AZN) Wednesday said its Tezspire (tezepelumab) has been approved in the European Union for the treatment of severe asthma. Tezspire is ...See details»


AstraZeneca receives China green light for Lynparza

Source from : Proactiveinvestors UK - 9 days ago

The drug will be used as a maintenance treatment in women with an advanced form of ovarian cancer AstraZeneca PLC (LSE:AZN) said a drug it has developed jointly with Merck has been approved for ...See details»


astrazeneca-severe-asthma-treatment-tezspire-gets-japanese-nod-image

AstraZeneca severe asthma treatment Tezspire gets Japanese nod

Source from : Daily - 3 days ago

UK: AstraZeneca has announced that Tezspire (tezepelumab) has been approved in Japan for the treatment of bronchial asthma in patients with severe or refractory disease in whom asthma symptoms cannot ...See details»


Global PD-1/PDL-1 Inhibitor Market Report 2022: Featuring GSK, Bristol-Myers Squibb, AstraZeneca, & Others

Source from : YAHOO!Finance - 2 days ago

Inhibitor Market - A Global and Regional Analysis: Focus on Epidemiology, Product, and Region - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.See details»


astrazeneca-mercks-koselugo-gets-approval-in-japan-for-rare-genetic-disorder-in-kids-image

AstraZeneca, Merck's Koselugo gets approval in Japan for rare genetic disorder in kids

Source from : Seeking Alpha - 4 days ago

Koselugo was approved in Japan to treat patients three years of age and older with plexiform neurofibromas (PNs) in neurofibromatosis type 1 ...See details»